In contrast with our findings from mouse PDAC tumor model, loss of SMAD4 in human pancreatic cancer patients was frequently identified and was associated with poor survival.[34] Such discrepancy may be due to the multiple functions of SMAD4 in pancreatic cancer development, differentiation, immune regulation at different cancer stages. This evidence concerns the gene SMAD4 and familial pancreatic carcinoma.